{
    "symbol": "RPRX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-08 10:40:05",
    "content": " And second, while we are optimistic heading into Pfizer's PFUFA for intranasal zavegepant in the first quarter of 2023, which would result in an accelerated $475 million payment to Royalty Pharma if approved, we do not plan to include that milestone in our 2023 guidance before approval. I think when you put together the size of the asthma market, which we all know is one of the largest commercial markets out there, AstraZeneca's long and enduring infrastructure in this setting and the fact that consensus for PT027 is nearly $1 billion by 2030 is that we are really excited about the commercial opportunity. And so, getting from the #2 billion to $2.5 billion that we have guided for sort of $4 billion to $5 billion should happen over time and will also be a function of us having those larger one-off transactions included over the next three to five years, and I think it's likely that we will have those larger transactions."
}